NBY
NovaBay Pharmaceuticals, Inc.
Set alert
- YTD
- -94.79%
- 1 year
- -47.32%
- Open
- 1.47
- Prev close
- 1.47
- Mkt cap
- 2.52M
- Vol
- 86.83K
- Avg vol
- 476.87K
- EPS
- -74.61
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.47
- High
- 1.47
- Forward P/E
- -0.63
- Beta
- 0.00
- Short ratio
- 0.07
- Inst. own
- 2.58%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.6314
- 200-d avg
- 1.85
- 1y target
- 3.73
Key statistics
- Market cap
- 2.52M
- Enterprise value
- 3.08M
- Trailing P/E
- 0.00
- Forward P/E
- -0.63
- PEG ratio
- 0.00
- Price / sales
- 0.19
- Price / book
- 2.37
- EPS (TTM)
- -74.61
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -77.48%
- Revenue (TTM)
- 13.06M
- Revenue growth
- -25.20%
- Free cash flow
- 295.75K
- Total cash
- 776.00K
- Total debt
- 1.26M
- Return on equity
- -263.83%
- Shares outstanding
- 4.89M
- Short % of float
- 1.50%
- 50-day average
- 0.6314
- 200-day average
- 1.85
Analyst view
Consensus: none
- Target (low)
- 0.85
- Target (mean)
- 3.73
- Target (high)
- 6.60
- Strong buy0
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.24.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2024 | Ascendiant Capital | main | Buy | Buy |
| Aug 11, 2023 | Ladenburg Thalmann | main | Buy | Buy |
About NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals, Inc. develops and sells eyecare and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health. The company also provides wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. It sells its products through the company's web stores, third-party online retailers and distribution partners. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- novabay.com
News
- NovaBay Rebrands To Stablecoin Development Corp In Full Crypto Pivot— Pharma Company's Stock Climbs 19%
- NovaBay Pharmaceuticals Announces Name Change to Stablecoin Development Corporation, Reports Initial Staking Rewards, and Provides SKY Token Holdings Update
- 12 Health Care Stocks Moving In Monday's Intraday Session
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- 12 Health Care Stocks Moving In Monday's Intraday Session
- 12 Health Care Stocks Moving In Friday's Intraday Session
- Netflix, Erasca, Kraft Heinz And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Your note
Sign in to keep a note on NBY — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FREIMAN PAUL EDWARD | Director | Conversion of Exercise of derivative security | May 10, 2023 | 1,783 |
| GARLIKOV JULIE | Director | Conversion of Exercise of derivative security | May 10, 2023 | 858 |
| SIT SWAN | Director | Conversion of Exercise of derivative security | May 10, 2023 | 1,716 |
| WU MIJIA | Director | Conversion of Exercise of derivative security | May 10, 2023 | 1,716 |
| ZHENG JEFF YENYOU | Director | Conversion of Exercise of derivative security | May 10, 2023 | 1,716 |
| ZHENG YONGXIANG | Director | Conversion of Exercise of derivative security | May 10, 2023 | 858 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| C2c Wealth Management, LLC | 0.88% | 42,948 | 22.19K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.54% | 26,337 | 13.61K | Sep 29, 2024 |
| UBS Group AG | 0.43% | 21,062 | 10.88K | Sep 29, 2024 |
| Virtu Financial LLC | 0.40% | 19,590 | 10.12K | Sep 29, 2024 |
| Warberg Asset Management LLC | 0.20% | 10,000 | 5.17K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.11% | 5,481 | 2.83K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.53% | 25,850 | 13.36K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.15% | 7,349 | 3.80K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.01% | 392 | 202 | Sep 29, 2024 |
| Blackstone Alternative Multi-Strategy Fund | 0.00% | 31 | 16 | Sep 29, 2024 |